ArticleResearch square2026
Barriers and Facilitators to Hepatitis C Virus Treatment in Los Angeles County.
Article in Research square, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
Diagnosed but untreated chronic Hepatitis C virus (HCV) infection is a major public health problem in Los Angeles (LA) County, particularly among underserved and minority groups. This mixed-methods study (October 2024-January 2025) used de-identified programmatic data from 344 case-residents in a linkage-to-cure program and conducted thematic analysis of semi-structured interviews with ten participants (seven untreated, three treated) from the linkage-to-cure program. By integrating these quantitative and qualitative findings, the study identified community-level and individual barriers and facilitators to HCV treatment. Quantitatively, 54% of case-residents reported barriers, such as personal barriers, provider-specific barriers, insurance barriers, and inadequate access to medical care. Qualitative themes expanded on these findings, identifying homelessness, incarceration, and drug addiction as key personal barriers. Provider-related barriers included language barriers, frustration in navigating the healthcare system, long wait times to see a provider, and participants' lack of HCV information. Insurance barriers were characterized by cost barriers and inadequate access to medical care due to a lack of transportation. Facilitators of treatment included personal motivation to seek treatment, family and community-based support systems, trust in their medical provider, adequate insurance coverage, understanding the benefits of HCV treatment, and the desire to avoid stigmatization. Eliminating HCV as a public health problem requires equitable interventions that address individual and system-level barriers. These include implementing language support services, leveraging patient navigation and care coordination services, utilizing mobile clinics for the unhoused, ensuring treatment continuity for people re-entering the community from incarceration, and removing insurance restrictions, such as prior authorization requirements.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.